Privium Fund Management Reduces Arrowhead Holdings Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy ARWR?
Source: Fool
Arrowhead Pharmaceuticals Inc. shares fell by 5.09% as it crossed below its 5-day SMA, reflecting broader market trends with the Nasdaq-100 down 1.44% and S&P 500 down 0.22%.
Privium Fund Management disclosed in a February 2 SEC filing that it reduced its position in Arrowhead Pharmaceuticals by 75,747 shares in Q4, with an estimated trade value of $3.71 million, reflecting a risk management strategy. Despite the reduction, the value of Arrowhead in Privium's portfolio surged by $10.09 million at quarter-end, indicating a strong stock price increase of 289.5% year-over-year, significantly outperforming the S&P 500's 15% gain. This suggests that while there is some selling pressure, investor confidence remains strong due to Arrowhead's projected fiscal 2025 revenue of $829 million, driven by licensing and milestone payments.
The reduction in shares by Privium may signal a cautious approach amid market volatility, but the overall financial outlook for Arrowhead appears robust, showcasing its accelerated commercialization efforts and strong market demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 60.670
Low
35.00
Averages
82.00
High
110.00
Current: 60.670
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
- Significant Revenue Growth: CRISPR Therapeutics' gene-editing therapy Casgevy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand for treatments of sickle cell disease and transfusion-dependent beta thalassemia.
- Surge in Patient Treatments: In Q4, 64 patients received Casgevy infusions, with 147 initiating treatment in the first quarter of 2025, nearly tripling 2024 levels, suggesting that successful patient recruitment will drive substantial revenue growth in the future.
- Analyst Optimism: William Blair analyst Sami Corwin noted that the increase in first cell collections strengthens confidence in significantly higher revenue expectations for 2026, reflecting market confidence in CRISPR's future performance.
- Positive Technical Analysis: CRISPR Therapeutics' stock is currently trading 14.4% above its 20-day SMA and 3.0% above its 100-day SMA, indicating a strong short-term upward trend, while the stock has risen 33.31% over the past 12 months, approaching its 52-week highs.
See More
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
- Conference Schedule: Arrowhead Pharmaceuticals is set to participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, where it will conduct a fireside chat presentation to showcase its advancements in RNA interference therapies.
- Investor Engagement: The company will also hold a fireside chat presentation at the Leerink 2026 Global Healthcare Conference from March 8-11, 2026, along with 1x1 investor meetings aimed at strengthening connections with potential investors.
- Industry Summit Participation: Arrowhead will host an investor group dinner at the 2026 Jefferies Biotech on the Beach Summit from March 9-11, further enhancing its influence and visibility in the biotechnology sector.
- Global Healthcare Conference: The company plans to conduct 1x1 investor meetings at the Barclays 28th Annual Global Healthcare Conference from March 10-12, showcasing its innovative drug development capabilities in treating intractable diseases.
See More
Morgan Stanley Lowers Arrowhead Price Target to $78
- Sales Forecast Downgrade: Morgan Stanley has lowered Arrowhead Pharmaceuticals (ARWR)'s price target from $81 to $78, indicating that despite optimistic early launch trends, significant sales from familial chylomicronemia syndrome are expected to be limited in 2026, potentially impacting future revenues.
- Clinical Trial Progress: On January 27, Arrowhead announced the dosing of the first participants in its ARO-DIMER-PA clinical trial, aimed at treating atherosclerotic cardiovascular disease caused by mixed hyperlipidemia, showcasing the company's R&D potential in the cardiovascular space.
- Dual-Target Treatment Strategy: ARO-DIMER-PA aims to effectively lower lipid levels by simultaneously suppressing the APOC3 and PCSK9 genes, offering a novel approach for patients with elevated cholesterol and triglycerides, thereby enhancing Arrowhead's competitiveness in the biotech sector.
- RNA Interference Platform Advantage: Arrowhead's proprietary TRiM RNAi platform enables the development of targeted, durable therapies for previously “undruggable” conditions, advancing treatments across cardiometabolic, rare genetic, and other diseases, highlighting its significant role in biopharmaceutical innovation.
See More
Strategic Shift in Biotech Dealmaking
- Biotech Deal Trends: Pharmaceutical companies are increasingly prioritizing late-stage assets with clinical validation over early-stage projects, positioning firms like Oncotelic Therapeutics as strategic assets capable of accelerating commercialization pathways.
- IP Expansion: Oncotelic Therapeutics announced enhancements to its OT-101 platform's international intellectual property protection in neurology and oncology, which will bolster its competitive edge in treating complex biological mechanisms.
- Strengthened Clinical Foundation: OT-101 has demonstrated strong performance in multiple oncology trials, recently securing a patent for Parkinson's disease in Australia, laying a solid foundation for future commercialization efforts.
- Cross-Indication Opportunities: Oncotelic's R&D strategy focuses on the TGF-β signaling pathway, which is significant in both oncology and neurological diseases, indicating potential value and strategic flexibility across multiple markets.
See More
Strategic Shift in Biopharma Dealmaking
- Strategic Transformation: Pharmaceutical companies are increasingly prioritizing late-stage assets with clinical validation over early-stage projects, positioning Oncotelic Therapeutics as a focal point due to its multiple clinical-stage programs in oncology and CNS, aligning with current M&A priorities.
- IP Expansion: Oncotelic Therapeutics announced enhancements to its global intellectual property protection for the OT-101 platform, particularly in drug delivery for neurology and oncology, which will bolster its competitive edge and strategic value in the market.
- Market Demand: The rising need for treatments for CNS disorders such as Alzheimer's and Parkinson's highlights the potential of Oncotelic's OT-101 platform, which targets the TGF-β signaling pathway to address these significant unmet medical needs.
- Capital Efficiency: The biotech industry is increasingly emphasizing capital efficiency, and Oncotelic's strategy of repositioning clinically validated mechanisms into additional therapeutic indications reduces risk while maximizing the value of prior investments, enhancing its market appeal.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
- Significant Revenue Growth: CRISPR Therapeutics' gene-editing therapy Casgevy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand for treatments of sickle cell disease and transfusion-dependent beta thalassemia.
- Surge in Patient Treatments: In Q4, 64 patients received Casgevy infusions, with 147 initiating treatment in the first quarter of 2025, nearly tripling 2024 levels, suggesting that successful patient recruitment will drive substantial revenue growth in the future.
- Analyst Optimism: William Blair analyst Sami Corwin noted that the increase in first cell collections strengthens confidence in significantly higher revenue expectations for 2026, reflecting market confidence in CRISPR's future performance.
- Positive Technical Analysis: CRISPR Therapeutics' stock is currently trading 14.4% above its 20-day SMA and 3.0% above its 100-day SMA, indicating a strong short-term upward trend, while the stock has risen 33.31% over the past 12 months, approaching its 52-week highs.
See More
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
- Conference Schedule: Arrowhead Pharmaceuticals is set to participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, where it will conduct a fireside chat presentation to showcase its advancements in RNA interference therapies.
- Investor Engagement: The company will also hold a fireside chat presentation at the Leerink 2026 Global Healthcare Conference from March 8-11, 2026, along with 1x1 investor meetings aimed at strengthening connections with potential investors.
- Industry Summit Participation: Arrowhead will host an investor group dinner at the 2026 Jefferies Biotech on the Beach Summit from March 9-11, further enhancing its influence and visibility in the biotechnology sector.
- Global Healthcare Conference: The company plans to conduct 1x1 investor meetings at the Barclays 28th Annual Global Healthcare Conference from March 10-12, showcasing its innovative drug development capabilities in treating intractable diseases.
See More
Morgan Stanley Lowers Arrowhead Price Target to $78
- Sales Forecast Downgrade: Morgan Stanley has lowered Arrowhead Pharmaceuticals (ARWR)'s price target from $81 to $78, indicating that despite optimistic early launch trends, significant sales from familial chylomicronemia syndrome are expected to be limited in 2026, potentially impacting future revenues.
- Clinical Trial Progress: On January 27, Arrowhead announced the dosing of the first participants in its ARO-DIMER-PA clinical trial, aimed at treating atherosclerotic cardiovascular disease caused by mixed hyperlipidemia, showcasing the company's R&D potential in the cardiovascular space.
- Dual-Target Treatment Strategy: ARO-DIMER-PA aims to effectively lower lipid levels by simultaneously suppressing the APOC3 and PCSK9 genes, offering a novel approach for patients with elevated cholesterol and triglycerides, thereby enhancing Arrowhead's competitiveness in the biotech sector.
- RNA Interference Platform Advantage: Arrowhead's proprietary TRiM RNAi platform enables the development of targeted, durable therapies for previously “undruggable” conditions, advancing treatments across cardiometabolic, rare genetic, and other diseases, highlighting its significant role in biopharmaceutical innovation.
See More
Strategic Shift in Biotech Dealmaking
- Biotech Deal Trends: Pharmaceutical companies are increasingly prioritizing late-stage assets with clinical validation over early-stage projects, positioning firms like Oncotelic Therapeutics as strategic assets capable of accelerating commercialization pathways.
- IP Expansion: Oncotelic Therapeutics announced enhancements to its OT-101 platform's international intellectual property protection in neurology and oncology, which will bolster its competitive edge in treating complex biological mechanisms.
- Strengthened Clinical Foundation: OT-101 has demonstrated strong performance in multiple oncology trials, recently securing a patent for Parkinson's disease in Australia, laying a solid foundation for future commercialization efforts.
- Cross-Indication Opportunities: Oncotelic's R&D strategy focuses on the TGF-β signaling pathway, which is significant in both oncology and neurological diseases, indicating potential value and strategic flexibility across multiple markets.
See More
Strategic Shift in Biopharma Dealmaking
- Strategic Transformation: Pharmaceutical companies are increasingly prioritizing late-stage assets with clinical validation over early-stage projects, positioning Oncotelic Therapeutics as a focal point due to its multiple clinical-stage programs in oncology and CNS, aligning with current M&A priorities.
- IP Expansion: Oncotelic Therapeutics announced enhancements to its global intellectual property protection for the OT-101 platform, particularly in drug delivery for neurology and oncology, which will bolster its competitive edge and strategic value in the market.
- Market Demand: The rising need for treatments for CNS disorders such as Alzheimer's and Parkinson's highlights the potential of Oncotelic's OT-101 platform, which targets the TGF-β signaling pathway to address these significant unmet medical needs.
- Capital Efficiency: The biotech industry is increasingly emphasizing capital efficiency, and Oncotelic's strategy of repositioning clinically validated mechanisms into additional therapeutic indications reduces risk while maximizing the value of prior investments, enhancing its market appeal.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
